Loading...

Scott Lippman

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0658
La Jolla CA 92093
Phone858-822-1222
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting Signaling Vulnerabilities for Oral Cancer Prevention
    NIH/NIDCR R01DE026644Jan 1, 2017 - Dec 31, 2021
    Role: Co-Principal Investigator
    Biology of the Prostate Cancer Prevention Trial (PCPT)
    NIH/NCI P01CA108964May 1, 2005 - Apr 30, 2013
    Role: Principal Investigator
    Molecular-Based Therapy for Oral Cancer Prevention
    NIH/NCI P01CA106451Aug 1, 2004 - Jul 31, 2012
    Role: Principal Investigator
    U10 Full Member Application Affiliated with SWOG
    NIH/NCI U10CA105409Jul 26, 2004 - Dec 31, 2015
    Role: Principal Investigator
    Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents
    NIH/NCI N01CN35159-8-0-1Sep 30, 2003 - Sep 29, 2012
    Role: Principal Investigator
    Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents
    NIH/NCI N01CN35159Sep 30, 2003 - Sep 29, 2008
    Role: Principal Investigator
    M D Anderson Cancer Center Head &Neck SPORE
    NIH/NCI P50CA097007Sep 30, 2002 - Jul 31, 2014
    Role: Principal Investigator
    PHASE III STUDY OF FENRETINIDE IN BLADDER CARCINOFENESIS
    NIH/NCI U01CA077150Sep 30, 1997 - Jul 31, 2004
    Role: Principal Investigator
    BIOLOGY OF NONMELANOMA SKIN CANCER GROWTH &PROGRESSION
    NIH P01CA068233May 6, 1996 - Mar 31, 2005
    Role: Co-Investigator
    PHASE II CLINICAL TRIALS OF NEW CHEMOPRVENTIVE AGENTS
    NIH/NCI N01CN065004Oct 2, 1995 - Jun 30, 2000
    Role: Principal Investigator
    BIOLOGY AND CHEMOPREVENTION OF HEAD AND NECK CANCER
    NIH P01CA052051Aug 5, 1991 - Nov 30, 2004
    Role: Co-Investigator
    Specialized Cancer Center Support Grant
    NIH/NCI P30CA023100Apr 1, 1978 - Apr 30, 2019
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman S, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 Jun 14. PMID: 29902298.
      View in: PubMed
    2. Orosco RK, Tapia VJ, Califano JA, Clary B, Cohen EEW, Kane C, Lippman S, Messer K, Molinolo A, Murphy JD, Pang J, Sacco A, Tringale KR, Wallace A, Nguyen QT. Positive Surgical Margins in the 10 Most Common Solid Cancers. Sci Rep. 2018 Apr 09; 8(1):5686. PMID: 29632347.
      View in: PubMed
    3. Saintigny P, William WN, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman S. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 Mar 01; 110(3). PMID: 29617836.
      View in: PubMed
    4. Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist. 2018 May; 23(5):586-593. PMID: 29487225.
      View in: PubMed
    5. Ha D, Ries AL, Mazzone PJ, Lippman S, Fuster MM. Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer. Support Care Cancer. 2018 Feb 10. PMID: 29429006.
      View in: PubMed
    6. Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman S, Thompson IM, Ambrosone CB. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis. 2018 Feb 09; 39(2):125-133. PMID: 29228205.
      View in: PubMed
    7. Deng Y, Tu H, Pierzynski JA, Miller ED, Gu X, Huang M, Chang DW, Ye Y, Hildebrandt MAT, Klein AP, Zhao R, Lippman S, Wu X. Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2018 Mar; 92:20-32. PMID: 29413686.
      View in: PubMed
    8. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman S, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 Nov; 18(11):e653-e706. PMID: 29208398.
      View in: PubMed
    9. William WN, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2. PMID: 28964539.
      View in: PubMed
    10. Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman S, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev. 2017 Oct; 26(10):1549-1557. PMID: 28754796.
      View in: PubMed
    11. Kerr J, Anderson C, Lippman S. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017 Aug; 18(8):e457-e471. PMID: 28759385.
      View in: PubMed
    12. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman S, Lanman RB, Kurzrock R. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017 08 15; 77(16):4238-4246. PMID: 28642281.
      View in: PubMed
    13. Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman S, Kurzrock R. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Mol Cancer Ther. 2017 May; 16(5):948-955. PMID: 28468865.
      View in: PubMed
    14. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman S, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723. PMID: 28420725.
      View in: PubMed
    15. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman S. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 04 01; 77(7):1510-1541. PMID: 28373404.
      View in: PubMed
    16. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman S, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate. 2017 Jun; 77(8):908-919. PMID: 28317149.
      View in: PubMed
    17. Dasanu CA, Argote JA, Lippman S, Plaxe SC. Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer. J Oncol Pharm Pract. 2018 Apr; 24(3):229-231. PMID: 28436313.
      View in: PubMed
    18. Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, Wu X, DeBoever C, Van Nostrand EL, Song Y, Wheeler E, Kreisberg JF, Lippman S, Yeo GW, Gutkind JS, Ideker T. Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. Cancer Discov. 2017 04; 7(4):410-423. PMID: 28188128.
      View in: PubMed
    19. Yurgelun MB, Chenevix-Trench G, Lippman S. Translating Germline Cancer Risk into Precision Prevention. Cell. 2017 Feb 09; 168(4):566-570. PMID: 28187278.
      View in: PubMed
    20. Krishnan AR, Korrapati A, Zou AE, Qu Y, Wang XQ, Califano JA, Wang-Rodriguez J, Lippman S, Hovell MF, Ongkeko WM. Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma. Oral Oncol. 2017 Feb; 65:68-75. PMID: 28109471.
      View in: PubMed
    21. McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman S. Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank. Cancer Prev Res (Phila). 2017 Feb; 10(2):99-107. PMID: 27965286.
      View in: PubMed
    22. Wu X, Wen CP, Ye Y, Tsai M, Wen C, Roth JA, Pu X, Chow WH, Huff C, Cunningham S, Huang M, Wu S, Tsao CK, Gu J, Lippman S. Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. Sci Rep. 2016 11 02; 6:36482. PMID: 27805040.
      View in: PubMed
    23. Dasanu CA, Lippman S, Plaxe SC. Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer. J Oncol Pharm Pract. 2017 Dec; 23(8):638-640. PMID: 27824586.
      View in: PubMed
    24. Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman S, Cohen EE, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun. 2016 Oct 04; 7:13019. PMID: 27698471.
      View in: PubMed
    25. Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman S. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A. 2016 09 27; 113(39):10750-8. PMID: 27638202.
      View in: PubMed
    26. Owens RL, Gold KA, Gozal D, Peppard PE, Jun JC, Lippman S, Malhotra A. Sleep and Breathing … and Cancer? Cancer Prev Res (Phila). 2016 Nov; 9(11):821-827. PMID: 27604751.
      View in: PubMed
    27. Zou AE, Zheng H, Saad MA, Rahimy M, Ku J, Kuo SZ, Honda TK, Wang-Rodriguez J, Xuan Y, Korrapati A, Yu V, Singh P, Grandis JR, King CC, Lippman S, Wang XQ, Hinton A, Ongkeko WM. The non-coding landscape of head and neck squamous cell carcinoma. Oncotarget. 2016 08 09; 7(32):51211-51222. PMID: 27323410.
      View in: PubMed
    28. Foy JP, Tortereau A, Caulin C, Le Texier V, Lavergne E, Thomas E, Chabaud S, Perol D, Lachuer J, Lang W, Hong WK, Goudot P, Lippman S, Bertolus C, Saintigny P. The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. Oncotarget. 2016 Jun 14; 7(24):35932-35945. PMID: 27027432.
      View in: PubMed
    29. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman S, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77. PMID: 27287781.
      View in: PubMed
    30. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman S, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462; PMCID: PMC4909608.
    31. Kato S, Lippman S, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 08; 108(8). PMID: 27059373.
      View in: PubMed
    32. Guertin KA, Grant RK, Arnold KB, Burwell L, Hartline J, Goodman PJ, Minasian LM, Lippman S, Klein E, Cassano PA. Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. Free Radic Biol Med. 2016 06; 95:349-56. PMID: 27012420; PMCID: PMC4867301 [Available on 06/01/17].
    33. Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman S, Luo J, Gutkind JS. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709. PMID: 26882569; PMCID: PMC4905432.
    34. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman S, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 04; 15(4):743-52. PMID: 26873727.
      View in: PubMed
    35. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman S. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16. PMID: 26540028; PMCID: PMC4771491 [Available on 02/01/17].
    36. Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman S, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate. 2016 May; 76(6):565-74. PMID: 26771888; PMCID: PMC4841624 [Available on 05/01/17].
    37. Lippman S. Catalyzing Cancer Prevention Research CaPR: A New Year/New Opportunities. Cancer Prev Res (Phila). 2016 Jan; 9(1):1. PMID: 26744448.
      View in: PubMed
    38. Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman S. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila). 2016 Jan; 9(1):2-10. PMID: 26744449; PMCID: PMC4955753 [Available on 01/01/17].
    39. Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM, Goodman PJ, Kristal AR, Parnes HL, Lippman S, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):463-9. PMID: 26715424; PMCID: PMC4779655 [Available on 03/01/17].
    40. Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman S, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst. 2016 Feb; 108(2). PMID: 26547931; PMCID: PMC4907357 [Available on 02/01/17].
    41. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman S, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.
    42. Joe AK, Schnoll-Sussman F, Bresalier RS, Abrams JA, Hibshoosh H, Cheung K, Friedman RA, Yang CS, Milne GL, Liu DD, Lee JJ, Abdul K, Bigg M, Foreman J, Su T, Wang X, Ahmed A, Neugut AI, Akpa E, Lippman S, Perloff M, Brown PH, Lightdale CJ. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus. Cancer Prev Res (Phila). 2015 Dec; 8(12):1131-7. PMID: 26471236; PMCID: PMC4670789 [Available on 12/01/16].
    43. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman S, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015 Nov; 8(11):1027-35. PMID: 26342026; PMCID: PMC4777304 [Available on 11/01/16].
    44. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. 2015 Sep-Oct; 65(5):345-83. PMID: 26284997; PMCID: PMC4820069.
    45. Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM, Lippman S, Platz EA, Schenk J. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1507-15. PMID: 26269564; PMCID: PMC4592455 [Available on 10/01/16].
    46. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman S, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    47. Kim JS, Kim ES, Liu D, Lee JJ, Behrens C, Lippman S, Hong WK, Wistuba II, Lee E, Lee HY. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget. 2015 Jun 30; 6(18):16746-56. PMID: 25944691; PMCID: PMC4599304.
    48. Krogan NJ, Lippman S, Agard DA, Ashworth A, Ideker T. The cancer cell map initiative: defining the hallmark networks of cancer. Mol Cell. 2015 May 21; 58(4):690-8. PMID: 26000852.
      View in: PubMed
    49. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman S, Song X, Gurel B, De Marzo A, Platz EA. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2015 Jul; 8(7):590-6. PMID: 25926387; PMCID: PMC4491033.
    50. Heaphy CM, Gaonkar G, Peskoe SB, Joshu CE, De Marzo AM, Lucia MS, Goodman PJ, Lippman S, Thompson IM, Platz EA, Meeker AK. Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2015 Aug 01; 75(11):1160-6. PMID: 25893825; PMCID: PMC4475463.
    51. Cassano PA, Guertin KA, Kristal AR, Ritchie KE, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, Minasian LM, Lippman S, Klein E. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. Respir Res. 2015 Mar 11; 16:35. PMID: 25889509; PMCID: PMC4404242.
    52. Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman S, Ambrosone CB, Thompson IM. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology. 2015 Mar; 85(3):616-20. PMID: 25733274; PMCID: PMC4348556.
    53. Raju SC, Hauff SJ, Lemieux AJ, Orosco RK, Gross AM, Nguyen LT, Savariar E, Moss W, Whitney M, Cohen EE, Lippman S, Tsien RY, Ideker T, Advani SJ, Nguyen QT. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015 May; 51(5):470-5. PMID: 25735654; PMCID: PMC4427339.
    54. Kim ES, Ye Y, Vaporciyan AA, Xing J, Huang M, Gu J, Roth JA, Lippman S, Wu X. Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study. J Thorac Oncol. 2015 Feb; 10(2):302-8. PMID: 25299235; PMCID: PMC4305022.
    55. Christen WG, Glynn RJ, Gaziano JM, Darke AK, Crowley JJ, Goodman PJ, Lippman S, Lad TE, Bearden JD, Goodman GE, Minasian LM, Thompson IM, Blanke CD, Klein EA. Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. JAMA Ophthalmol. 2015 Jan; 133(1):17-24. PMID: 25232809; PMCID: PMC4395006.
    56. Wen CP, Zhang F, Liang D, Wen C, Gu J, Skinner H, Chow WH, Ye Y, Pu X, Hildebrandt MA, Huang M, Chen CH, Hsiung CA, Tsai MK, Tsao CK, Lippman S, Wu X. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res. 2015 Jan 01; 21(1):193-200. PMID: 25336700; PMCID: PMC4286447.
    57. Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman S, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014 Dec 15; 20(24):6570-81. PMID: 25316813; PMCID: PMC4268116.
    58. Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman S, Kaye SB, Carden CP. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700. PMID: 25208878.
      View in: PubMed
    59. Hauff SJ, Raju SC, Orosco RK, Gross AM, Diaz-Perez JA, Savariar E, Nashi N, Hasselman J, Whitney M, Myers JN, Lippman S, Tsien RY, Ideker T, Nguyen QT. Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice. Otolaryngol Head Neck Surg. 2014 Oct; 151(4):612-8. PMID: 25091190; PMCID: PMC4469264.
    60. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman S, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664; PMCID: PMC4146706.
    61. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman S, Kurzrock R. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821; PMCID: PMC4041669.
    62. Pu X, Hildebrandt MA, Lu C, Roth JA, Stewart DJ, Zhao Y, Heist RS, Ye Y, Chang DW, Su L, Minna JD, Lippman S, Spitz MR, Christiani DC, Wu X. Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369. PMID: 24755914; PMCID: PMC4141040.
    63. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman S, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441.
      View in: PubMed
    64. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman S, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):847-56. PMID: 24748218; PMCID: PMC4012292.
    65. He Y, Gong Y, Gu J, Lee JJ, Lippman S, Wu X. Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. Carcinogenesis. 2014 Aug; 35(8):1760-4. PMID: 24743515; PMCID: PMC4123647.
    66. Greenwald P, Stoner G, Colburn N, Lippman S. John A. Milner: in memoriam (1947-2013). Cancer Prev Res (Phila). 2014 Apr; 7(4):373-4. PMID: 24695271.
      View in: PubMed
    67. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman S, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014 Mar; 106(3):djt456. PMID: 24563519; PMCID: PMC3975165.
    68. Lippman S. Letter from the Editor. Cancer Prev Res (Phila). 2014 Feb; 7(2):179-81. PMID: 24464731.
      View in: PubMed
    69. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman S, Hong WK, Wistuba II, Lee HY. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21. PMID: 24485233; PMCID: PMC4572464.
    70. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman S. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906; PMCID: PMC3905243.
    71. Falchook GS, Lippman S, Bastida CC, Kurzrock R. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck. 2014 Mar; 36(3):E25-7. PMID: 23852769; PMCID: PMC3893310.
    72. Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman S, Glisson BS, Lee HY. Combating resistance to anti-IGFR antibody by targeting the integrin ß3-Src pathway. J Natl Cancer Inst. 2013 Oct 16; 105(20):1558-70. PMID: 24092920; PMCID: PMC3797025.
    73. Bau DT, Lippman S, Xu E, Gong Y, Lee JJ, Wu X, Gu J. Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer. 2013 Dec 15; 119(24):4277-83. PMID: 24105340; PMCID: PMC3855186.
    74. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman S, Ruckdeschel J, Khuri FR. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol. 2013 Nov 20; 31(33):4179-87. PMID: 24002495; PMCID: PMC3821010.
    75. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG, Wade JL, Lippman S. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10; 31(23):2942-62. PMID: 23835710.
      View in: PubMed
    76. Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman S, El-Naggar AK. MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome. PLoS One. 2013; 8(6):e66778. PMID: 23825564; PMCID: PMC3692530.
    77. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR, Butler AP, Gamble J, Gamble S, Hardy C, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, McLaren S, McBride DJ, Menzies A, Mudie L, Maddison M, Raine K, Nik-Zainal S, O'Meara S, Teague JW, Varela I, Wedge DC, Whitmore I, Lippman S, McDermott U, Stratton MR, Campbell PJ, El-Naggar AK, Futreal PA. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013 Jul; 123(7):2965-8. PMID: 23778141.
      View in: PubMed
    78. Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman S, Ye Y, Minna JD, Wu X. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 2013 Aug 01; 73(15):4801-9. PMID: 23774211; PMCID: PMC3760306.
    79. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman S, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res. 2013 Jul 01; 73(13):4028-38. PMID: 23704207; PMCID: PMC3719971.
    80. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298.
      View in: PubMed
    81. Zhang L, Mitani Y, Caulin C, Rao PH, Kies MS, Saintigny P, Zhang N, Weber RS, Lippman S, El-Naggar AK. Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol. 2013 Jun; 182(6):2048-57. PMID: 23583282; PMCID: PMC3668022.
    82. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman S, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42. PMID: 23442309; PMCID: PMC3879952.
    83. Pu X, Roth JA, Hildebrandt MA, Ye Y, Wei H, Minna JD, Lippman S, Wu X. MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res. 2013 Mar 15; 73(6):1867-75. PMID: 23378343; PMCID: PMC3602350.
    84. Wang JL, Gold KA, Lippman S. Natural-agent mechanisms and early-phase clinical development. Top Curr Chem. 2013; 329:241-52. PMID: 22851156.
      View in: PubMed
    85. Lippman S. Looking forward to 2013--saluting the exceptional year in 2012. Cancer Prev Res (Phila). 2013 Jan; 6(1):1-3. PMID: 23282630.
      View in: PubMed
    86. Yan W, Shih J, Rodriguez-Canales J, Tangrea MA, Player A, Diao L, Hu N, Goldstein AM, Wang J, Taylor PR, Lippman S, Wistuba II, Emmert-Buck MR, Erickson HS. Three-dimensional mRNA measurements reveal minimal regional heterogeneity in esophageal squamous cell carcinoma. Am J Pathol. 2013 Feb; 182(2):529-39. PMID: 23219752; PMCID: PMC3562732.
    87. El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11. PMID: 23229707.
      View in: PubMed
    88. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman S, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15; 73(2):571-82. PMID: 23204236; PMCID: PMC3548940.
    89. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780.
      View in: PubMed
    90. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman S, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90. PMID: 23091115; PMCID: PMC3567921.
    91. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman S, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res. 2012 Nov 01; 18(21):5983-91. PMID: 22977190; PMCID: PMC3640870.
    92. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman S, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811. PMID: 22961666; PMCID: PMC3567922.
    93. Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman S, Hsing AW. Associations of serum sex steroid hormone and 5a-androstane-3a,17ß-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1823-32. PMID: 22879203; PMCID: PMC3467348.
    94. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman S, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54. PMID: 22827973; PMCID: PMC3816771.
    95. Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman S, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 2012 Sep; 11(9):2021-32. PMID: 22807579; PMCID: PMC3438283.
    96. Lin J, Lu C, Stewart DJ, Gu J, Huang M, Chang DW, Lippman S, Wu X. Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis. 2012 Sep; 33(9):1699-706. PMID: 22665367; PMCID: PMC3514904.
    97. Hildebrandt MA, Lippman S, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13. PMID: 22577058; PMCID: PMC3404728.
    98. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman S, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 2012 Aug 15; 118(16):3993-4003. PMID: 22359227; PMCID: PMC3674414.
    99. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman S, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021; PMCID: PMC3274509.
    100. Santarpia L, Lippman S, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1):103-19. PMID: 22239440; PMCID: PMC3457779.
    101. Lippman S. Letter from the editor. Cancer Prev Res (Phila). 2012 Jan; 5(1):1-2. PMID: 22219161.
      View in: PubMed
    102. Wu X, Lippman S. An intermittent approach for cancer chemoprevention. Nat Rev Cancer. 2011 11 10; 11(12):879-85. PMID: 22071977.
      View in: PubMed
    103. Chan AT, Lippman S. Aspirin and colorectal cancer prevention in Lynch syndrome. Lancet. 2011 Dec 17; 378(9809):2051-2. PMID: 22036018.
      View in: PubMed
    104. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman S, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12; 306(14):1549-56. PMID: 21990298; PMCID: PMC4169010.
    105. Shin DH, Min HY, El-Naggar AK, Lippman S, Glisson B, Lee HY. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther. 2011 Dec; 10(12):2437-48. PMID: 21980128; PMCID: PMC3237768.
    106. Mitani Y, Rao PH, Futreal PA, Roberts DB, Stephens PJ, Zhao YJ, Zhang L, Mitani M, Weber RS, Lippman S, Caulin C, El-Naggar AK. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res. 2011 Nov 15; 17(22):7003-14. PMID: 21976542.
      View in: PubMed
    107. Yin J, Lu C, Gu J, Lippman S, Hildebrandt MA, Lin J, Stewart D, Spitz MR, Wu X. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis. 2011 Dec; 32(12):1867-71. PMID: 21965272; PMCID: PMC3220611.
    108. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman S, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012 May 01; 118(9):2454-65. PMID: 21952750; PMCID: PMC3298843.
    109. Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman S, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila). 2011 Nov; 4(11):1761-9. PMID: 21896650; PMCID: PMC3208719.
    110. Tang L, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Kristal AR, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JK, Santella RM, Hsing A, Hoque A, Lippman S, Thompson IM, Ambrosone CB. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis. 2011 Oct; 32(10):1500-6. PMID: 21771722; PMCID: PMC3179424.
    111. Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman S, Thompson IM, Ambrosone CB, Hoque A. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control. 2011 Aug; 22(8):1121-31. PMID: 21667068; PMCID: PMC3139891.
    112. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman S, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319; PMCID: PMC4211116.
    113. Kim JH, Choi DS, Lee OH, Oh SH, Lippman S, Lee HY. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood. 2011 Sep 01; 118(9):2622-31. PMID: 21551235; PMCID: PMC3167363.
    114. Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman S, Wu X. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis. 2011 Jul; 32(7):1050-6. PMID: 21515830; PMCID: PMC3128559.
    115. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman S, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25. PMID: 21483023; PMCID: PMC3096796.
    116. Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman S, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila). 2011 Jan; 4(1):34-42. PMID: 21163939.
      View in: PubMed
    117. Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman S. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila). 2010 Dec; 3(12):1523-33. PMID: 21149329; PMCID: PMC3058741.
    118. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman S, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15. PMID: 20855820; PMCID: PMC2974341.
    119. Zhang X, Yang H, Lee JJ, Kim E, Lippman S, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis. 2010 Dec; 31(12):2118-23. PMID: 20819778; PMCID: PMC3105587.
    120. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman S, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402. PMID: 20811626; PMCID: PMC2928273.
    121. Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman S, Szabo E, Bonanni B. Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. Contemp Clin Trials. 2010 Nov; 31(6):612-9. PMID: 20719253.
      View in: PubMed
    122. Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman S, Weber RS, Caulin C, El-Naggar AK. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010 Oct 01; 16(19):4722-31. PMID: 20702610.
      View in: PubMed
    123. Wang J, Lippman S, Lee JJ, Yang H, Khuri FR, Kim E, Lin J, Chang DW, Lotan R, Hong WK, Wu X. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis. 2010 Oct; 31(10):1755-61. PMID: 20627871; PMCID: PMC2950933.
    124. Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman S, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol. 2010 Aug 01; 28(22):3611-6. PMID: 20606094; PMCID: PMC2917316.
    125. Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman S, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol. 2010 Jul; 5(7):940-9. PMID: 20512076; PMCID: PMC3782111.
    126. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman S, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010 Jun 29; 2:15. PMID: 20587061; PMCID: PMC2908081.
    127. Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman S. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res (Phila). 2010 Jul; 3(7):829-38. PMID: 20570882; PMCID: PMC2900425.
    128. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman S, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63. PMID: 20530716; PMCID: PMC2913168.
    129. Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman S. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prev Res (Phila). 2010 Jun; 3(6):738-44. PMID: 20501862; PMCID: PMC2881192.
    130. William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman S, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8. PMID: 20225327.
      View in: PubMed
    131. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman S, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52. PMID: 19687727.
      View in: PubMed
    132. Blackburn EH, Tlsty TD, Lippman S. Unprecedented opportunities and promise for cancer prevention research. Cancer Prev Res (Phila). 2010 Apr; 3(4):394-402. PMID: 20354163.
      View in: PubMed
    133. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman S, Schwartz DL. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74. PMID: 20171802; PMCID: PMC3072063.
    134. Clague J, Lippman S, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog. 2010 Feb; 49(2):183-9. PMID: 19851984; PMCID: PMC3640857.
    135. Wang LE, Hu Z, Sturgis EM, Spitz MR, Strom SS, Amos CI, Guo Z, Qiao Y, Gillenwater AM, Myers JN, Clayman GL, Weber RS, El-Naggar AK, Mao L, Lippman S, Hong WK, Wei Q. Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res. 2010 Jan 15; 16(2):764-74. PMID: 20068090; PMCID: PMC2848391.
    136. Musumeci L, Arthur JW, Cheung FS, Hoque A, Lippman S, Reichardt JK. Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies. Hum Mutat. 2010 Jan; 31(1):67-73. PMID: 19877174; PMCID: PMC2797835.
    137. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman S, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14. PMID: 19917840; PMCID: PMC2799235.
    138. Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, Subbaramaiah K, Morrow JD, Milne G, Lippman S, Dannenberg AJ. Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila). 2009 Nov; 2(11):957-65. PMID: 19843689; PMCID: PMC2784194.
    139. Visvanathan K, Lippman S, Hurley P, Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol. 2009 Oct; 115(1):132-4. PMID: 19716939; PMCID: PMC4119170.
    140. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman S, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 01; 15(19):6284-91. PMID: 19773378; PMCID: PMC2756317.
    141. Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman S, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009 Sep 15; 69(18):7439-48. PMID: 19738076; PMCID: PMC2745504.
    142. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman S, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience. Oncology. 2009; 77(2):75-81. PMID: 19571599; PMCID: PMC2790774.
    143. Wu X, Spitz MR, Lee JJ, Lippman S, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009 Jul; 2(7):617-24. PMID: 19584075; PMCID: PMC2964280.
    144. Platz EA, Lippman S. Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial. J Clin Oncol. 2009 Aug 01; 27(22):3569-72. PMID: 19528369.
      View in: PubMed
    145. Lippman S, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009 Jul 01; 69(13):5269-84. PMID: 19491253.
      View in: PubMed
    146. Lippman S. Cancer prevention research: back to the future. Cancer Prev Res (Phila). 2009 Jun; 2(6):503-13. PMID: 19491288.
      View in: PubMed
    147. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman S. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 01; 27(19):3235-58. PMID: 19470930; PMCID: PMC2716943.
    148. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of phase 1 cancer clinical trials: new challenges in study requirements. Cancer. 2009 Apr 15; 115(8):1592-7. PMID: 19165808; PMCID: PMC2668727.
    149. Pu X, Lippman S, Yang H, Lee JJ, Wu X. Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer. 2009 Apr 01; 115(7):1498-506. PMID: 19197984; PMCID: PMC2666299.
    150. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman S, Schwartz DL. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15. PMID: 19332725; PMCID: PMC2739610.
    151. William WN, Lin HY, Lee JJ, Lippman S, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep; 136(3):701-709. PMID: 19318668.
      View in: PubMed
    152. Zinner RG, Barrett BL, Popova E, Damien P, Volgin AY, Gelovani JG, Lotan R, Tran HT, Pisano C, Mills GB, Mao L, Hong WK, Lippman S, Miller JH. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther. 2009 Mar; 8(3):521-32. PMID: 19276160.
      View in: PubMed
    153. Kristal AR, Lippman S. Nutritional prevention of cancer: new directions for an increasingly complex challenge. J Natl Cancer Inst. 2009 Mar 18; 101(6):363-5. PMID: 19276449.
      View in: PubMed
    154. William WN, Heymach JV, Kim ES, Lippman S. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009 Mar; 8(3):213-25. PMID: 19247304.
      View in: PubMed
    155. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman S, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175; PMCID: PMC2734116.
    156. William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman S, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9. PMID: 19194117.
      View in: PubMed
    157. William WN, Lee JJ, Lippman S, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6. PMID: 19139014; PMCID: PMC4161148.
    158. Lippman S. Cancer Prevention Research. Letter from the Editor. Cancer Prev Res (Phila). 2009 Jan; 2(1):1-2. PMID: 19139009.
      View in: PubMed
    159. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman S, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21. PMID: 19139013; PMCID: PMC4243520.
    160. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman S. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604. PMID: 19075276; PMCID: PMC2645856.
    161. Lippman S, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51. PMID: 19066370; PMCID: PMC3682779.
    162. Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349; author reply 1350. PMID: 19059972.
      View in: PubMed
    163. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman S, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008 Nov 22; 372(9652):1809-18. PMID: 19027483.
      View in: PubMed
    164. Lippman S. The future of molecular-targeted cancer chemoprevention. Gastroenterology. 2008 Dec; 135(6):1834-41. PMID: 18996123.
      View in: PubMed
    165. Ye Y, Lippman S, Lee JJ, Chen M, Frazier ML, Spitz MR, Wu X. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer. 2008 Nov 01; 113(9):2488-95. PMID: 18823025; PMCID: PMC2577230.
    166. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman S. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5. PMID: 18990728.
      View in: PubMed
    167. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman S. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5. PMID: 19138984.
      View in: PubMed
    168. Howe LR, Lippman S. Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst. 2008 Oct 15; 100(20):1420-3. PMID: 18840814; PMCID: PMC2567416.
    169. Herbst RS, Heymach JV, Lippman S. Lung cancer. N Engl J Med. 2008 Sep 25; 359(13):1367-80. PMID: 18815398.
      View in: PubMed
    170. Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman S, Wistuba II, Koo JS. Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Res. 2008 Aug 01; 68(15):6065-73. PMID: 18676828; PMCID: PMC3058903.
    171. Yang H, Lippman S, Huang M, Jack Lee J, Wang W, Spitz MR, Wu X. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur J Cancer. 2008 Jul; 44(11):1603-11. PMID: 18579371; PMCID: PMC2603619.
    172. Lippman S. Inaugural issue of Cancer Prevention Research. Cancer Prev Res (Phila). 2008 Jun; 1(1):1-3. PMID: 19138928.
      View in: PubMed
    173. Mandal M, Myers JN, Lippman S, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008 May 01; 112(9):2088-100. PMID: 18327819.
      View in: PubMed
    174. Thompson IM, Tangen CM, Parnes HL, Lippman S, Coltman CA. Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology. 2008 May; 71(5):854-7. PMID: 18455628; PMCID: PMC2692669.
    175. Goodwin JW, Green SJ, Moinpour CM, Bearden JD, Giguere JK, Jiang CS, Lippman S, Martino S, Albain KS. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008 Apr 01; 26(10):1650-6. PMID: 18375894.
      View in: PubMed
    176. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman S, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101. PMID: 18381950.
      View in: PubMed
    177. Svatek RS, Lee JJ, Roehrborn CG, Lippman S, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008 Mar 01; 112(5):1058-65. PMID: 18186497.
      View in: PubMed
    178. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman S, Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008 Jan 20; 26(3):354-60. PMID: 18202409.
      View in: PubMed
    179. Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman S, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. FASEB J. 2008 Jun; 22(6):1981-92. PMID: 18198215; PMCID: PMC2410033.
    180. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman S. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9. PMID: 18172274.
      View in: PubMed
    181. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman S, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res. 2007 Nov 01; 13(21):6532-9. PMID: 17975167.
      View in: PubMed
    182. Hoque A, Parnes HL, Stefanek ME, Heymach JV, Brown PH, Lippman S. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res. 2007 Oct 01; 67(19):8989-93. PMID: 17895292.
      View in: PubMed
    183. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman S, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19; 99(18):1375-83. PMID: 17848673.
      View in: PubMed
    184. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman S, Lucia MS, Parnes HL, Coltman CA. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20; 25(21):3076-81. PMID: 17634486.
      View in: PubMed
    185. Lippman S, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res. 2007 Jul 15; 13(14):4035-41. PMID: 17634526.
      View in: PubMed
    186. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, Patrick DL, Ware JE, Ganz PA, Shumaker SA, Lippman S, Coltman CA. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Jul 04; 99(13):1025-35. PMID: 17596576.
      View in: PubMed
    187. Wang Y, Spitz MR, Lee JJ, Huang M, Lippman S, Wu X. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res. 2007 Jun 15; 13(12):3753-8. PMID: 17575242.
      View in: PubMed
    188. Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman S. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007 May 20; 25(15):1974-8. PMID: 17513803.
      View in: PubMed
    189. Gotay CC, Moinpour CM, Unger JM, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil S, Gross HM, Lippman S, Albain KS. Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. J Clin Oncol. 2007 May 20; 25(15):2093-9. PMID: 17513815.
      View in: PubMed
    190. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman S, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007 Jul; 178(1):107-9; discussion 110. PMID: 17499284.
      View in: PubMed
    191. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman S, Coltman CA. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007 May; 177(5):1749-52. PMID: 17437804.
      View in: PubMed
    192. Herbst RS, Lippman S. Molecular signatures of lung cancer--toward personalized therapy. N Engl J Med. 2007 Jan 04; 356(1):76-8. PMID: 17202459.
      View in: PubMed
    193. Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman S. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB J. 2007 Mar; 21(3):743-53. PMID: 17167069; PMCID: PMC1847772.
    194. Herberman RB, Pearce HL, Lippman S, Pyenson BS, Alberts DS. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need. Cancer Res. 2006 Dec 15; 66(24):11540-9. PMID: 17158189.
      View in: PubMed
    195. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman S, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1977-83. PMID: 17035408.
      View in: PubMed
    196. Lippman S. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol. 2006 Oct; 3(10):523. PMID: 17019426.
      View in: PubMed
    197. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman S, Lucia MS, Parnes HL, Coltman CA. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1128-33. PMID: 16912265.
      View in: PubMed
    198. Svatek RS, Lee JJ, Roehrborn CG, Lippman S, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1485-9. PMID: 16896037.
      View in: PubMed
    199. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman S, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1479-84. PMID: 16896036.
      View in: PubMed
    200. Liang ZD, Lippman S, Wu TT, Lotan R, Xu XC. RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoA. Cancer Res. 2006 Jul 15; 66(14):7111-8. PMID: 16849557.
      View in: PubMed
    201. Wang LE, Hsu TC, Xiong P, Strom SS, Duvic M, Clayman GL, Weber RS, Lippman S, Goldberg LH, Wei Q. 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysis. J Invest Dermatol. 2007 Jan; 127(1):196-205. PMID: 16841033.
      View in: PubMed
    202. Kelloff GJ, Lippman S, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      View in: PubMed
    203. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman S, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21; 295(23):2727-41. PMID: 16754727.
      View in: PubMed
    204. The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol. 2006 Jun 20; 24(18):2948-57. PMID: 16702579.
      View in: PubMed
    205. Lippman S, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14. PMID: 16707609.
      View in: PubMed
    206. Huang M, Spitz MR, Gu J, Lee JJ, Lin J, Lippman S, Wu X. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis. 2006 Oct; 27(10):2034-7. PMID: 16638786.
      View in: PubMed
    207. Khuri FR, Lee JJ, Lippman S, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50. PMID: 16595780.
      View in: PubMed
    208. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman S. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84. PMID: 16609032.
      View in: PubMed
    209. Lippman S, Lee JJ. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res. 2006 Mar 15; 66(6):2893-903. PMID: 16540634.
      View in: PubMed
    210. Li G, Yin W, Chamberlain R, Hewett-Emmett D, Roberts JN, Yang X, Lippman S, Clifford JL. Identification and characterization of the human retinoid X receptor alpha gene promoter. Gene. 2006 May 10; 372:118-27. PMID: 16517099.
      View in: PubMed
    211. Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, Clayman GL, Weber RS, Lippman S, Amos CI, Spitz MR, Wei Q. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31. PMID: 16368944.
      View in: PubMed
    212. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman S. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005 Dec 15; 65(24):11486-92. PMID: 16357157; PMCID: PMC1564070.
    213. Song S, Lippman S, Zou Y, Ye X, Ajani JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene. 2005 Dec 15; 24(56):8268-76. PMID: 16170369.
      View in: PubMed
    214. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman S. Statins and cancer prevention. Nat Rev Cancer. 2005 Dec; 5(12):930-42. PMID: 16341084.
      View in: PubMed
    215. Sabichi AL, Xu X, Lippman S. RARbeta1': primed to fight retinoid resistance in lung carcinogenesis. J Natl Cancer Inst. 2005 Nov 16; 97(22):1632-3. PMID: 16288110.
      View in: PubMed
    216. Thompson IM, Tangen CM, Klein EA, Lippman S. Phase III prostate cancer prevention trials: are the costs justified? J Clin Oncol. 2005 Nov 10; 23(32):8161-4. PMID: 16278467.
      View in: PubMed
    217. Hsi LC, Xi X, Wu Y, Lippman S. The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Mol Cancer Ther. 2005 Nov; 4(11):1740-6. PMID: 16275995.
      View in: PubMed
    218. Mayne ST, Lippman S. Cigarettes: a smoking gun in cancer chemoprevention. J Natl Cancer Inst. 2005 Sep 21; 97(18):1319-21. PMID: 16174848.
      View in: PubMed
    219. Deguchi A, Xing SW, Shureiqi I, Yang P, Newman RA, Lippman S, Feinmark SJ, Oehlen B, Weinstein IB. Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res. 2005 Sep 15; 65(18):8442-7. PMID: 16166323.
      View in: PubMed
    220. Klein EA, Tangen CM, Goodman PJ, Lippman S, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. J Clin Oncol. 2005 Oct 20; 23(30):7460-6. PMID: 16157937.
      View in: PubMed
    221. Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, Lee JJ, Lippman S, Clayman GL. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7. PMID: 16148695.
      View in: PubMed
    222. Lippman S, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res. 2005 Sep 01; 11(17):6097-9. PMID: 16144906.
      View in: PubMed
    223. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman S, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 2005 Jul 15; 65(14):6189-98. PMID: 16024620.
      View in: PubMed
    224. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman S, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702. PMID: 16030104.
      View in: PubMed
    225. Hirsch FR, Lippman S. Advances in the biology of lung cancer chemoprevention. J Clin Oncol. 2005 May 10; 23(14):3186-97. PMID: 15886305.
      View in: PubMed
    226. Ewer MS, Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005 May 01; 23(13):2900-2. PMID: 15860848.
      View in: PubMed
    227. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman S. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):826-9. PMID: 15824151.
      View in: PubMed
    228. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman S, Lee JJ, Zheng W, Balmain A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis. 2005 Aug; 26(8):1368-73. PMID: 15802297.
      View in: PubMed
    229. Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman S. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol. 2005 Mar 20; 23(9):1911-20. PMID: 15774783.
      View in: PubMed
    230. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman S, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia. 2005 Mar; 7(3):280-93. PMID: 15799828; PMCID: PMC1501140.
    231. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman S. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005 Feb 01; 23(4):759-65. PMID: 15681519.
      View in: PubMed
    232. Hoque A, Lippman S, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr; 26(4):785-91. PMID: 15661803.
      View in: PubMed
    233. Lippman S, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005 Jan 19; 97(2):94-102. PMID: 15657339.
      View in: PubMed
    234. Lippman S, Sudbø J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol. 2005 Jan 10; 23(2):346-56. PMID: 15637397.
      View in: PubMed
    235. Dannenberg AJ, Lippman S, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005 Jan 10; 23(2):254-66. PMID: 15637389.
      View in: PubMed
    236. Lippman S, Levin B. Cancer prevention: strong science and real medicine. J Clin Oncol. 2005 Jan 10; 23(2):249-53. PMID: 15637388.
      View in: PubMed
    237. Cook ED, Moody-Thomas S, Anderson KB, Campbell R, Hamilton SJ, Harrington JM, Lippman S, Minasian LM, Paskett ED, Craine S, Arnold KB, Probstfield JL. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials. 2005; 2(5):436-42. PMID: 16315648.
      View in: PubMed
    238. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman S. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res. 2004 Dec 01; 64(23):8778-81. PMID: 15574791.
      View in: PubMed
    239. Duffield-Lillico AJ, Shureiqi I, Lippman S. Can selenium prevent colorectal cancer? A signpost from epidemiology. J Natl Cancer Inst. 2004 Nov 17; 96(22):1645-7. PMID: 15547171.
      View in: PubMed
    240. Sabichi AL, Subbarayan V, Llansa N, Lippman S, Menter DG. Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1704-9. PMID: 15533896.
      View in: PubMed
    241. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman S, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1710-6. PMID: 15533897.
      View in: PubMed
    242. Abbruzzese JL, Lippman S. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell. 2004 Oct; 6(4):321-6. PMID: 15488755.
      View in: PubMed
    243. Lippman S, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, Garber JE, Hawk E, Ganz PA, Somerfield MR. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol. 2004 Oct 01; 22(19):3848-51. PMID: 15353541.
      View in: PubMed
    244. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman S, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27; 350(22):2239-46. PMID: 15163773.
      View in: PubMed
    245. Taylor PR, Parnes HL, Lippman S. Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst. 2004 May 05; 96(9):645-7. PMID: 15126594.
      View in: PubMed
    246. Sabichi AL, Lippman S. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):36-44. PMID: 15179622.
      View in: PubMed
    247. Liu J, Baykal A, Fung KM, Thompson-Lanza JA, Hoque A, Lippman S, Sahin A. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol. 2004 Apr; 24(4):879-84. PMID: 15010825.
      View in: PubMed
    248. Sudbø J, Lippman S, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004 Apr 01; 350(14):1405-13. PMID: 15070790.
      View in: PubMed
    249. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman S, Hong WK, Lotan R. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res. 2004 Mar 01; 10(5):1733-42. PMID: 15014026.
      View in: PubMed
    250. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman S, Frye R, Cavanaugh PF. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004 Mar 01; 10(5):1565-73. PMID: 15014005.
      View in: PubMed
    251. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman S, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004 Apr 30; 279(18):19191-200. PMID: 14985354.
      View in: PubMed
    252. Thompson IM, Klein EA, Lippman S, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003 Dec; 44(6):650-5. PMID: 14644115.
      View in: PubMed
    253. Sudbø J, Bryne M, Mao L, Lotan R, Reith A, Kildal W, Davidson B, Søland TM, Lippman S. Molecular based treatment of oral cancer. Oral Oncol. 2003 Dec; 39(8):749-58. PMID: 13679198.
      View in: PubMed
    254. Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S, Lippman S. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev. 2003 Dec; 12(12):1518-22. PMID: 14693746.
      View in: PubMed
    255. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman S, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23. PMID: 14601092.
      View in: PubMed
    256. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman S, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52. PMID: 14597742; PMCID: PMC4523388.
    257. Rice D, Kim HW, Sabichi A, Lippman S, Lee JJ, Williams B, Vaporciyan A, Smythe WR, Swisher S, Walsh G, Putnam JB, Hong WK, Roth J. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003 Oct; 76(4):1001-7; discussion 1007-8. PMID: 14529975.
      View in: PubMed
    258. Chu DZ, Chansky K, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman S. Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. Ann Surg Oncol. 2003 Oct; 10(8):870-5. PMID: 14527904.
      View in: PubMed
    259. Jiang F, Caraway NP, Sabichi AL, Zhang HZ, Ruitrok A, Grossman HB, Gu J, Lerner SP, Lippman S, Katz RL. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003 Sep 20; 106(5):661-5. PMID: 12866024.
      View in: PubMed
    260. Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman S. Frontiers in cancer prevention research. Cancer Res. 2003 Sep 15; 63(18):5649-55. PMID: 14522879.
      View in: PubMed
    261. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman S, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3660-6. PMID: 14506155.
      View in: PubMed
    262. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman S. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9968-73. PMID: 12909723; PMCID: PMC187904.
    263. Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman S, Menter DG. Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem. 2003 Oct 17; 278(42):41338-46. PMID: 12900420.
      View in: PubMed
    264. Sabichi AL, Modiano MR, Lee JJ, Peng YM, Xu MJ, Villar H, Dalton WS, Lippman S. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul; 9(7):2400-5. PMID: 12855611.
      View in: PubMed
    265. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman S, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17; 349(3):215-24. PMID: 12824459.
      View in: PubMed
    266. Clifford JL, Yang X, Walch E, Wang M, Lippman S. Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. Mol Cancer Ther. 2003 May; 2(5):453-9. PMID: 12748307.
      View in: PubMed
    267. Liang Z, Lippman S, Kawabe A, Shimada Y, Xu XC. Identification of benzo(a)pyrene diol epoxide-binding DNA fragments using DNA immunoprecipitation technique. Cancer Res. 2003 Apr 01; 63(7):1470-4. PMID: 12670892.
      View in: PubMed
    268. Klein EA, Lippman S, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C. The selenium and vitamin E cancer prevention trial. World J Urol. 2003 May; 21(1):21-7. PMID: 12756490.
      View in: PubMed
    269. Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, Lippman S. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia. 2003 Mar-Apr; 5(2):121-7. PMID: 12659684; PMCID: PMC1502398.
    270. Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A, Lippman S, Kripke ML, Ananthaswamy HN. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res. 2003 Jan; 9(1):228-34. PMID: 12538474.
      View in: PubMed
    271. Sabichi AL, Lippman S. COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res. 2003; 37:163-78. PMID: 12795054.
      View in: PubMed
    272. Klein EA, Thompson IM, Lippman S, Goodman PJ, Albanes D, Taylor PR, Coltman C. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol. 2003 Jan-Feb; 21(1):59-65. PMID: 12684129.
      View in: PubMed
    273. Lippman S, Hong WK. Cancer prevention science and practice. Cancer Res. 2002 Sep 15; 62(18):5119-25. PMID: 12234971.
      View in: PubMed
    274. Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman S. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res. 2002 Sep; 8(9):2835-42. PMID: 12231524.
      View in: PubMed
    275. Shin DM, Glisson BS, Khuri FR, Lippman S, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30. PMID: 12124833.
      View in: PubMed
    276. Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, El-Naggar AK, Lotan R, Lippman S. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res. 2002 Jul; 8(7):2067-72. PMID: 12114405.
      View in: PubMed
    277. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman S. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002 Jun; 11(6):587-90. PMID: 12050101.
      View in: PubMed
    278. Wu X, Lippman S, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002 May 15; 62(10):2813-8. PMID: 12019158.
      View in: PubMed
    279. Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, Lippman S. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res. 2002 Feb 15; 62(4):1178-83. PMID: 11861401.
      View in: PubMed
    280. Lippman S, Hong WK. Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. Clin Cancer Res. 2002 Feb; 8(2):305-13. PMID: 11839646.
      View in: PubMed
    281. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman S, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002 Feb; 8(2):314-46. PMID: 11839647.
      View in: PubMed
    282. Li M, Song S, Lippman S, Zhang XK, Liu X, Lotan R, Xu XC. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene. 2002 Jan 17; 21(3):411-8. PMID: 11821953.
      View in: PubMed
    283. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman S. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15; 20(2):364-70. PMID: 11786562.
      View in: PubMed